Stockscreener 앱 받기
2.31
1.28%
-0.03
시간 외 거래:
2.32
0.010
+0.43%
전일 마감가:
$2.34
열려 있는:
$2.34
하루 거래량:
64,397
Relative Volume:
0.38
시가총액:
$31.14M
수익:
-
순이익/손실:
$-43.10M
주가수익비율:
-0.2376
EPS:
-9.7212
순현금흐름:
$-36.82M
1주 성능:
+0.87%
1개월 성능:
+3.59%
6개월 성능:
-57.96%
1년 성능:
-56.40%
1일 변동 폭
$2.25
$2.46
1주일 범위
$2.13
$2.46
52주 변동 폭
$1.20
$6.115
Tempest Therapeutics Inc Stock (TPST) Company Profile
명칭
Tempest Therapeutics Inc
전화
415-798-8589
주소
2000 SIERRA POINT PARKWAY, BRISBANE
Compare TPST vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TPST
Tempest Therapeutics Inc
|
2.31 | 31.55M | 0 | -43.10M | -36.82M | -9.7212 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-22 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2025-04-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2025-04-10 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
| 2024-03-14 | 개시 | Scotiabank | Sector Outperform |
| 2024-02-08 | 개시 | Jefferies | Buy |
Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스
Earnings Recap: Is Tempest Therapeutics Inc stock a value trap2025 EndofYear Setup & Smart Swing Trading Techniques - baoquankhu1.vn
TPST Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Tempest Therapeutics, Inc. (TPST) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
Tempest Therapeutics, Inc.Common Stock (NQ: TPST - FinancialContent
EX-99.1 - SEC.gov
Tempest Therapeutics reports complete response in myeloma trial - Investing.com
Tempest Therapeutics Advances TPST-2003 CAR-T with Strong Data - TipRanks
Tempest reports 100% ORR in evaluable TPST-2003 patients, plans U.S. registrational study in 2026 - TradingView
Tempest Therapeutics (TPST) reveals 100% response in TPST-2003 multiple myeloma study - Stock Titan
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 - Bitget
Tempest myeloma cell therapy hits 100% response in 25 patients, US trial planned - Stock Titan
Tempest Therapeutics reports complete response in myeloma trial By Investing.com - Investing.com Canada
Why Tempest Therapeutics Inc. stock could outperform in 2025Weekly Profit Recap & Free Community Supported Trade Ideas - mfd.ru
How Tempest Therapeutics Inc. stock reacts to global recession fearsMarket Sentiment Report & AI Enhanced Execution Alerts - mfd.ru
Is Tempest Therapeutics Inc.’s growth already priced inBuy Signal & Daily Oversold Bounce Ideas - mfd.ru
What catalysts could drive Tempest Therapeutics Inc. stock higher2025 Earnings Impact & Free High Return Stock Watch Alerts - mfd.ru
Will Tempest Therapeutics Inc. stock recover after earningsM&A Rumor & Advanced Swing Trade Entry Plans - mfd.ru
TPST Should I Buy - Intellectia AI
How cyclical is Tempest Therapeutics Inc.’s revenue streamEarnings Performance Report & Smart Swing Trading Techniques - mfd.ru
Tempest Therapeutics Highlights Partner-Funded CAR-T Oncology Pipeline - The Globe and Mail
Tempest lays out strategic plan to advance recently acquired dual-targeting CAR-T assets - marketscreener.com
Tempest Therapeutics outlines plans for acquired CAR T assets - bioworld.com
Tempest Therapeutics, Inc. Updates on Oncology Pipeline and Clinical Progress - TradingView
Partner-funded China trials anchor Tempest’s new CAR-T push - Stock Titan
Tempest Lays Out Strategic Plan to Advance Recently Acquired Dual-Targeting CAR-T Assets - The Manila Times
Key facts: Tempest Therapeutics announces management changes; issues warrants - TradingView
Tempest Therapeutics Signs Warrant Agreement With Computershare - TradingView
Tempest Therapeutics (NASDAQ: TPST) closes CAR T acquisition and names new CEO - Stock Titan
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Tempest Announces Closing of Strategic Acquisition of Dual-Targeting CAR-T Assets - The Manila Times
Tempest Therapeutics completes acquisition of CAR-T assets By Investing.com - Investing.com Nigeria
Tempest Therapeutics completes acquisition of CAR-T assets - Investing.com
Tempest Therapeutics Closes All-Stock Transaction to Acquire Next-Generation CAR-T Assets and Appoints Matt Angel as CEO - Quiver Quantitative
Cancer biotech Tempest retools around dual CAR-Ts and new CEO - Stock Titan
Tempest Therapeutics (TPST) Price Target Increased by 22.22% to 11.22 - Nasdaq
Tempest Therapeutics Announces New Leadership and Acquisition - MSN
Will Tennessee Valley Authority benefit from AI trendsMarket Sentiment Summary & Weekly High Momentum Picks - baoquankhu1.vn
What’s the outlook for Tempest Therapeutics Inc.’s sectorPortfolio Gains Report & Consistent Return Investment Signals - mfd.ru
Tempest Therapeutics (NASDAQ: TPST) wins approval for rights plan, share issuance and equity pool - Stock Titan
Investment Report: Is Tempest Therapeutics Inc stock a value trapJuly 2025 Final Week & Daily Stock Trend Watchlist - baoquankhu1.vn
Aug Decliners: Is Tempest Therapeutics Inc stock a top performer YTD2025 EndofYear Setup & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Tempest Therapeutics stock surges after H.C. Wainwright upgrade By Investing.com - Investing.com Australia
Tempest Therapeutics stock surges after H.C. Wainwright upgrade - Investing.com
H.C. Wainwright upgrades Tempest Therapeutics stock rating to Buy with $11 target - Investing.com India
HC Wainwright & Co. Upgrades Tempest Therapeutics (TPST) - Nasdaq
Tempest Announces Record Date for Anticipated Dividend Distribution of Warrants to Stockholders - The Manila Times
Inflation Data: Will Tempest Therapeutics Inc stock recover after earningsJuly 2025 Update & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Tempest Therapeutics Announces Record Date for Warrant Dividends Distribution Following Asset Purchase Agreement - Quiver Quantitative
Cancer drug developer Tempest to hand out 1:1 stock warrants - Stock Titan
How risky is Tempest Therapeutics Inc. stock nowCEO Change & Precise Buy Zone Tips - bollywoodhelpline.com
Will Tempest Therapeutics Inc. stock pay special dividendsJuly 2025 Institutional & Entry Point Confirmation Signals - bollywoodhelpline.com
Tempest Therapeutics Inc (TPST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.69%
0.68%
자본화:
|
볼륨(24시간):